ArticleEinstein (Sao Paulo, Brazil)2025
Effects of 3'-sialyllactose, saliva, and colostrum on Candida albicans biofilms.
Article in Einstein (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaria et al. evaluated the initial adhesion and biofilm formation of Candida albicans in vitro in the presence of saliva, human colostrum, and 3'-sialyllactose. Colostrum applied either before or after inoculation with saliva did not differ from that of the control biofilms (p<0.05). In contrast, colostrum applied during C. albicans inoculation resulted in a higher biomass than the control (p<0.05). Saliva without colostrum decreased the biofilm biomass (p<0.05), and the application of 3'- sialyllactose reduced biofilm formation regardless of the timing of application (p<0.05). Candidiasis can present as localized or systemic infections. Disseminated infections in newborns and adults can be life-threatening, with high mortality and morbidity rates (40-60%), and rank as the fourth most common type of nosocomial infection. Oral candidiasis is a local condition affecting 10-15% of children in their first months of life. Saliva and 3'-sialyllactose can disrupt the initial development of Candida albicans biofilm. The effect of colostrum needs to be elucidated because it may hinder initial adhesion but promote fungal proliferation after application.
objectiveThe aim of this study was to investigate the effects of saliva, human colostrum, and 3'-sialyllactose on the initial adhesion and biofilm formation of Candida albicans in vitro.
methodsColostrum and saliva samples were collected from 30 postpartum mothers and newborns, respectively. An 18h culture of C. albicans was treated with colostrum, 3'-sialyllactose, saliva, or a combination of colostrum and saliva at three different time points: before, during, and 24h after C. albicans inoculation. Biofilm assays were conducted in sterile 96-well flat-bottom microtiter plates for 24h. Biofilms were fixed, washed, stained with crystal violet, and extracted. Absorbance was measured to evaluate biofilm biomass.
resultsThe combined application of colostrum and saliva before and after microbial inoculation did not differ from the control biofilms (p<0.05). In contrast, the combined application of colostrum and saliva during C. albicans application resulted in a higher biomass than the control (p<0.05). Saliva alone decreased the biofilm biomass (p<0.05), and the application of 3'-sialyllactose reduced biofilm formation regardless of the timing of application (p<0.05).
conclusionSaliva contributed to the proliferation of biofilms, while colostrum did not prevent initial adhesion but influenced biofilm accumulation and development. In contrast, 3'-sialyllactose significantly decreased biofilm formation at all application times. These findings underscore the importance of colostrum as a potent oral antimicrobial biofluid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.